RudaCure Pursues Global Partnering for RCI001/RCI002 and Expanded Gene Therapy Co-Development at 2025 BIO-USA
RudaCure Inc. a annoncé sa participation in the **BIO International Convention (BIO-USA)** 2025 held in the États-Unis, where it will conduct overseas licence and co-développement réunions de partenariat for its major pipelines: RCI001 (traitement de la sécheresse oculaire) and **RCI002 (TRPV1-targeted analgésique)**.
At the event, RudaCure will meet with world-renowned pharmaceutique ophtalmique companies notamment Santen of Japan and Thea of France to share the development status and national/international essai clinique progress of RCI001, and conduct in-depth discussions on co-développement and marché mondial entry possibilities.
In the field of analgésique development, l'entreprise plans to present the research results and commercial potential of RCI002 to major global entreprises pharmaceutiques. RCI002, a candidat-médicament innovant that simultaneously targets TRPV1 and MOR (Mu-Opioid Receptor), has demonstrated potent effets analgésiques at very low doses in études précliniques, earning attention as a analgésique non narcotique that overcomes the addiction and tolerance issues of opioid-based treatments. Various companies have shown strong interest, and this BIO-USA provides an important opportunity to explore specific concession de licence and co-développement models.
RudaCure is actuellement also pursuing co-développement of a gene therapy-based traitement de la douleur for vétérinaire use, leveraging its proprietary canal ionique-targeted peptide technology combined with AAV (Adeno-Associated Virus) vectors. This project, récemment selected for the Ministère de Agriculture's Agri-Food Venture Development Program, devrait serve as a plateforme technology applicable to both human and pharmaceutique vétérinaires, and discussions with multiple overseas partners devraient accelerate during BIO-USA.
le PDG Yongho Kim a déclaré : "BIO-USA 2025 will be a pivotal étape clé for RudaCure's expansion mondiale. Sur la base de the clinical outcomes of RCI001 and the innovant mechanism of RCI002, we will proactively advance partenariats with global entreprises pharmaceutiques and establish ourselves as a new drug developer with global presence."
